CC312 (anti-CD19×CD3×CD28) is the first trispecific antibody generated from CytoCares’ Tri-specific T-cell Engager (TriTETM）technology platform.
The mechanism of action of CC312 is the engagement of T cells through the CD3 chain of the T cell receptor complex and CD28 co-stimulatory receptor, resulting in sustainable T cell activation and direct T cell mediated killing of B cells. T cell activation is initiated upon binding of the antibody to the T cell receptor (TCR)/CD3 complex (“signal 1”); activation is enhanced by engagement of a second “co-stimulatory” receptor on T cells via agonist agent (“signal 2”). The extra engagement of a co-stimulatory receptor through the agonist agent has the capability of enhancing the artificial synapse between a T cell and its target cell, potentiating T cell activation, and achieving a durable and effective immune response to fight against cancer.
